Skip to content

Eeffective of pentoxifyllin on recurrence endometriosis

A Comparison study of effectivness of pentoxifyllin and LD in preventing recurrent endometriosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT201109087513N1
Enrollment
83
Registered
2012-05-02
Start date
2008-03-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis of uterus. Endometriosis of uterus

Interventions

Intervention 1: We used the visual analog scale (VAS) method for detecting the severity of the possible pain existence before and after the treatment period (the recurrence).Each treatment duration wa
Treatment - Drugs
We used the visual analog scale (VAS) method for detecting the severity of the possible pain existence before and after the treatment period (the recurrence).Each treatment duration was about 6months.
Group two: Pentoxifyllin capsules with the same dose plus OCP (LD) one tablet per night, from the third day of the menstrual cycle for 6 months.
Group three: OCP (LD) one tablet per night for21days then 7days rest and repaet it for 6 months

Sponsors

Isfahan University of Medical Sciences-Research Council
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 28 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diagnosed Laparascopic endometriosis with the clinical symptoms Exclusion criteria:Refusing the patient of entry to the protocol; The presence of the specific drug side effects

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain reilief. Timepoint: 6months. Method of measurement: Visual Analog Scale(VAS).;Endometriosis recurrence. Timepoint: after 6 months of follow up. Method of measurement: clinical assessment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojdeh Ghasemi

Isfahan University of Medical Sciences

md_ghasemi@yahoo.com/ research_beheshti@med.mui.ac.ir+98 913 319 1159

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026